Iovance Biotherapeutics
San Carlos, California, United States · Biotechnology, Health Care, Therapeutics · 804 employees
Iovance Biotherapeutics (NASDAQ: IOVA) aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promi
Funding history
- Venture - Series Unknown — $100.0M — Jun 2016
Recent signals
- Feb 16, 2025: Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer
- Jun 15, 2016: Raised $100.0M in Venture - Series Unknown
See plans & pricing → Track Iovance Biotherapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.